Search Results - "Urbani, Ginevra"
-
1
Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH
Published in Scientific reports (28-01-2023)“…Non-alcoholic steatosis (NAFLD) and steatohepatitis (NASH) are two highly prevalent human disorders for which therapy remains suboptimal. Bile acids are…”
Get full text
Journal Article -
2
Role of mRAGEs and ACE2 in SARS-CoV-2-Related Inflammation
Published in Recent advances in inflammation & allergy drug discovery (01-01-2022)Get more information
Journal Article -
3
Development of dual GPBAR1 agonist and RORγt inverse agonist for the treatment of inflammatory bowel diseases
Published in Pharmacological research (01-10-2024)“…Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are chronic disorders characterized by dysregulated immune response and…”
Get full text
Journal Article -
4
GDF15 in Vascular and Liver Metabolic Disorders: A Novel Therapeutic Target
Published in Recent advances in inflammation & allergy drug discovery (01-01-2022)Get more information
Journal Article -
5
Bile Acids-Based Therapies for Primary Sclerosing Cholangitis: Current Landscape and Future Developments
Published in Cells (Basel, Switzerland) (04-10-2024)“…Primary sclerosing cholangitis (PSC) is a rare, chronic liver disease with no approved therapies. The ursodeoxycholic acid (UDCA) has been widely used,…”
Get full text
Journal Article -
6
Current Landscape and Evolving Therapies for Primary Biliary Cholangitis
Published in Cells (Basel, Switzerland) (19-09-2024)“…Primary Biliary Cholangitis (PBC) is a chronic autoimmune liver disorder characterized by progressive cholestatic that, if untreated, can progress to liver…”
Get full text
Journal Article -
7
Next-Generation Sequencing Analysis of Gastric Cancer Identifies the Leukemia Inhibitory Factor Receptor as a Driving Factor in Gastric Cancer Progression and as a Predictor of Poor Prognosis
Published in Frontiers in oncology (30-06-2022)“…Gastric cancer (GC) is the third cause of cancer-related mortality worldwide. Nevertheless, because GC screening programs are not cost-effective, most patients…”
Get full text
Journal Article -
8
Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma
Published in Frontiers in oncology (14-03-2023)“…The leukemia inhibitory factor (LIF), is a cytokine belonging to IL-6 family, whose overexpression correlate with poor prognosis in cancer patients, including…”
Get full text
Journal Article -
9
Defective Bile Acid Signaling Promotes Vascular Dysfunction, Supporting a Role for G-Protein Bile Acid Receptor 1/Farnesoid X Receptor Agonism and Statins in the Treatment of Nonalcoholic Fatty Liver Disease
Published in Journal of the American Heart Association (05-12-2023)“…Patients with nonalcoholic fatty liver disease are at increased risk to develop atherosclerotic cardiovascular diseases. FXR and GPBAR1 are 2 bile…”
Get full text
Journal Article -
10
The leukemia inhibitory factor regulates fibroblast growth factor receptor 4 transcription in gastric cancer
Published in Cellular oncology (Dordrecht) (01-04-2024)“…Purpose The gastric adenocarcinoma (GC) represents the third cause of cancer-related mortality worldwide, and available therapeutic options remain sub-optimal…”
Get full text
Journal Article -
11
Repositioning Mifepristone as a Leukaemia Inhibitory Factor Receptor Antagonist for the Treatment of Pancreatic Adenocarcinoma
Published in Cells (Basel, Switzerland) (03-11-2022)“…Pancreatic cancer is a leading cause of cancer mortality and is projected to become the second-most common cause of cancer mortality in the next decade. While…”
Get full text
Journal Article -
12
Bile acids and bile acid activated receptors in the treatment of Covid-19
Published in Biochemical pharmacology (01-10-2024)“…[Display omitted] Since its first outbreak in 2020, the pandemic caused by the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) has caused the…”
Get full text
Journal Article -
13
Immunology of bile acids regulated receptors
Published in Progress in lipid research (01-07-2024)“…Bile acids are steroids formed at the interface of host metabolism and intestinal microbiota. While primary bile acids are generated in the liver from…”
Get full text
Journal Article -
14
Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling
Published in Biochimica et biophysica acta. Molecular and cell biology of lipids (01-11-2022)“…Non-alcoholic steatosis (NAFLD) and steatohepatitis (NASH) are two highly prevalent human disorders for which therapy remains suboptimal. Bile acids play an…”
Get full text
Journal Article -
15
Tu1726 GPBAR1 AGONISM AND SIMULTANEOUS RORΓT INVERSE AGONISM AS A NOVEL PROMISING THERAPY FOR THE TREATMENT OF IBD
Published in Gastroenterology (New York, N.Y. 1943) (18-05-2024)Get full text
Journal Article -
16
Sa1563 BAR502 AS A PROMISING THERAPY FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS: INSIGHTS FROM MURINE MODEL STUDIES
Published in Gastroenterology (New York, N.Y. 1943) (18-05-2024)Get full text
Journal Article -
17
-
18
-
19
217 BAR502, A DUAL FXR AND GPBAR1 AGONIST, SYNERGIZED ATORVASTATIN BENEFICIAL EFFECTS ON VASCULAR INFLAMMATION IN NASH
Published in Gastroenterology (New York, N.Y. 1943) (01-05-2023)Get full text
Journal Article -
20